Hana Klamová

Charles University — Czech Republic

Medicine · Health Sciences

23h-index2.8kcitations196works7.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(150), Chronic Lymphocytic Leukemia Research(110), Acute Lymphoblastic Leukemia research(35), Acute Myeloid Leukemia Research(33), Eosinophilic Disorders and Syndromes(26)

Publications196 total

Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia
Leukemia·2025Open Access
Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia
American Journal of Hematology·2025Open Access
Somatic Mutations and Outcomes in CML Adolescent and Young Adults Compared to Children, Adults, and BCR::ABL1-positive ALL Patients
2025· 1 citedOpen Access
Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
Cancer Medicine·2024· 3 citedOpen Access
Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression
Hematology Transfusion and Cell Therapy·2024· 1 citedOpen Access
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
Leukemia·2024· 6 citedOpen Access
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry
Leukemia·2024· 23 citedOpen Access
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
Leukemia·2024· 2 citedOpen Access
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
Journal of Clinical Oncology·2024· 47 citedOpen Access
Unstable major molecular response as a trigger for next generation sequencing‐based <i>BCR::ABL1</i> mutation testing in chronic myeloid leukemia
American Journal of Hematology·2024· 2 citedOpen Access
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors
American Journal of Hematology·2024· 3 citedOpen Access
A Short Retrospective Cytometric Note on Myeloblasts in Patients Suffering from Acute Myeloblastic Leukaemia, Myelodysplastic Syndrome and Chronic Myelocytic Leukaemia: Myeloblasts with a Narrow Cytoplasm without Azurophilic Granules Are Less Differentiated Committed Progenitor Stem Cells
Folia Biologica·2024Open Access
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
Leukemia·2023· 4 citedOpen Access
Somatic Mutations in Cancer-Related Genes Were Observed More Frequently in AYA CML Patients Compared to Elderly at Diagnosis, Whereas the Frequency Was Markedly Higher in Elderly Patients during TKI Treatment
Blood·2023
Real World Population- Based Data from Nationwide Registry Support the Existence of Accelerated Phase in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients Even in Tyrosine Kinase Inhibitors (TKIs) Era
Blood·2023· 1 cited
The Reduction of the Cell Nuclear Size in the Cell Body Space During the Differentiation Might Be Cell Lineage Specific (A Retrospective Morphological Note)
Physiological Research·2023· 1 citedOpen Access
P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE
HemaSphere·2023Open Access
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
2023Open Access
Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells
PLoS ONE·2023· 8 citedOpen Access
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value on treatment-free remission in chronic myeloid leukemia patients treated with imatinib
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Kateřina Machová Poláková(21), Jiřı́ Mayer(16), Daniela Žáčková(12), Jana Moravcová(11), Edgar Faber(10), Václava Polívková(9), Andreas Hochhaus(8), J Voglová(8), Petr Cetkovský(8), Delphine Réa(7), K Michalová(7), Susanne Saußele(6), Zdeněk Ráčil(6), Ulla Olsson‐Strömberg(5), Philippe Rousselot(5), Simona Soverini(5), Tereza Lopotová(5), Adela Benesova(5), Jana Březinová(5), Nikola Čuřík(5)